Protara Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M |
| Operating expenses | $64.5M | $49.2M | $43.6M | $67.1M | $47.5M |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | $57.4M | $44.6M | — | — | — |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | -$47.3M |
| Balance Sheet | |||||
| Cash and equivalents | $49.7M | $162.8M | $39.6M | $24.1M | $35.7M |
| Current assets | $159.5M | $172.2M | $68.7M | $86.1M | $93.1M |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M |
| Current liabilities | $10.9M | $11.0M | $6.1M | $5.7M | $4.3M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M |
| Stockholders' equity | $196.4M | $167.1M | $68.3M | $102.1M | $161.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M |
| Depreciation and amortization | $362,000 | $332,000 | $341,000 | $248,000 | $117,000 |
| Stock-based compensation | $3.8M | $4.1M | $6.1M | $6.7M | $10.4M |
| Capital expenditure | $94,000 | $63,000 | $45,000 | $120,000 | $596,000 |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M | -$35.1M |
| Share repurchases | — | — | $91,000 | $90,000 | $228,000 |
| Impairments | — | — | — | $29.5M | — |
Shares outstanding 56.2M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.